MedDataX Logo

Single Rising Dose Study (Intravenous Infusion and Subcutaneous Injection) of BI 655064 in Healthy Male Volunteers

NCT ID: NCT01510782

Last Updated: 2013-11-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

72 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-01-31

Study Completion Date

2012-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To investigate safety and tolerability of BI 655064 in healthy male volunteers following intravenous infusion of escalating single doses and following subcutaneous injection. Exploration of the pharmacokinetics and pharmacodynamics of BI 655064 after single dosing and determination of the bioavailability of subcutaneous injections of BI 655064.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Single Rising Dose Study of BI 655088 Administered Intravenously in Healthy Male Volunteers

NCT02696616

Healthy
COMPLETED PHASE1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 1356 BS in Healthy Male Volunteers

NCT02183298

Healthy
COMPLETED PHASE1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 10773 in Healthy Male Subjects

NCT02172170

Healthy
COMPLETED PHASE1

Single Rising Dose Study to Assess Safety, Tolerability and Pharmacokinetics of BI 661051.

NCT01343719

Healthy
COMPLETED PHASE1

A Study in Healthy Men to Test How Different Doses of BI 3032950 Are Tolerated

NCT05518708

Healthy
COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BI 655064 subcutaneous

Escalating single dose as solution for subcutaneous injection

Group Type EXPERIMENTAL

BI 655064

Intervention Type DRUG

subcutaneous injection of escalating doses

Placebo to BI 655064 subcutaneous

Escalation single dose as solution for subcutaneous injection (Placebo)

Group Type PLACEBO_COMPARATOR

Placebo to BI 655064

Intervention Type DRUG

subcutaneous injection of escalating doses

BI 655064 intravenous

Escalating single dose as solution for intravenous infusion

Group Type EXPERIMENTAL

BI 655064

Intervention Type DRUG

intravenous infusion of escalating doses

Placebo to BI 655064 intravenous

Escalating single dose as solution for intravenous infusion (Placebo)

Group Type PLACEBO_COMPARATOR

Placebo to BI 655064

Intervention Type DRUG

intravenous infusion of escalating doses

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo to BI 655064

intravenous infusion of escalating doses

Intervention Type DRUG

Placebo to BI 655064

subcutaneous injection of escalating doses

Intervention Type DRUG

BI 655064

intravenous infusion of escalating doses

Intervention Type DRUG

BI 655064

subcutaneous injection of escalating doses

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1\. Healthy male subjects

Exclusion Criteria

1\. Any relevant deviation from healthy conditions
Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

1293.1.1 Boehringer Ingelheim Investigational Site

Berlin, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

References

Explore related publications, articles, or registry entries linked to this study.

Albach FN, Wagner F, Huser A, Igel J, Joseph D, Hilbert J, Schoelch C, Padula SJ, Steffgen J. Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases. Eur J Clin Pharmacol. 2018 Feb;74(2):161-169. doi: 10.1007/s00228-017-2362-8. Epub 2017 Nov 10.

Reference Type DERIVED
PMID: 29127458 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2011-002251-34

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

1293.1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Safety, Tolerability and Pharmacokinetics Study of BI 1744 CL in Healthy Male Subjects
NCT02172131 TERMINATED PHASE1
A Study to Test How Well Healthy Men Tolerate BI 765250 When Given as an Infusion Into the Vein or as an Injection Under the Skin
NCT05151653 COMPLETED PHASE1
Safety and Pharmacokinetics of Single Rising Doses of BI 705564 and Food Effect on BI 705564 in Healthy Male Subjects
NCT03123185 COMPLETED PHASE1
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 639667
NCT02133482 WITHDRAWN PHASE1
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
NCT05515328 COMPLETED PHASE1
Safety, Tolerability and Pharmacokinetics of Single Rising Intravenous Doses of BI 44370 BS Solution in Healthy Male Volunteers
NCT02215031 COMPLETED PHASE1
Single Rising Oral Doses of BI 207127 NA as Powder in the Bottle in Healthy Male Subjects
NCT02182388 COMPLETED PHASE1
A Study in Healthy People to Measure the Amount of BI 655130 in the Blood After Injecting Different Doses Into Different Parts of the Body
NCT03617835 COMPLETED PHASE1
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses and Multiple Rising Oral Doses of BI 1356 BS in Healthy Male Volunteers
NCT02183311 COMPLETED PHASE1
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 706321
NCT03971695 COMPLETED PHASE1
Single Rising Dose Study of BI 201335 ZW in Healthy Male Subjects
NCT02182271 TERMINATED PHASE1
Safety, Tolerability, Pharmacokinetics and Early Pharmacodynamics of Single Rising Oral Doses of BI 1021958 Tablets in Healthy Male Volunteers
NCT01541488 COMPLETED PHASE1
This Study Tests How Healthy Men Tolerate Different Doses of BI1015550. The Study Also Tests How BI 1015550 is Taken up by the Body
NCT03230487 COMPLETED PHASE1
Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1015550 in Healthy Male Volunteers
NCT01594515 COMPLETED PHASE1
Investigation of Single Rising Doses of BI 685509
NCT02694354 COMPLETED PHASE1
Safety, Tolerability, and Pharmacokinetics of a Subcutaneous and Intravenous Dose of BI 655130 in Healthy Subjects
NCT03100903 COMPLETED PHASE1
A Study in Healthy Men to Test How BI 1015550 is Taken up and Handled by the Body
NCT05707403 COMPLETED PHASE1
Safety, Tolerability, Pharmacokinetics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers, Including Investigation of the Effect of Food on the Bioavailability of BI 1181181
NCT02044406 COMPLETED PHASE1
A Bioavailability and Pharmacokinetic Study of Subcutaneous and Intravenous RO6811135 in Healthy Volunteers
NCT01802853 COMPLETED PHASE1
A Study in Healthy Men Tests How Different Doses of BI 764198 Are Taken up in the Body and How Well They Are Tolerated.
NCT03854552 COMPLETED PHASE1
Single Increasing Dose Tolerance Study in Healthy Male Volunteers of BIIR 561 CL
NCT02222974 COMPLETED PHASE1
A Study to Test How Well Different Doses of BI 3810477 Are Tolerated by Healthy Men
NCT06631430 COMPLETED PHASE1
A Study in Healthy Men to Test How Different Doses of BI 3031185 Are Tolerated and How Food Influences the Amount of BI 3031185 in the Blood
NCT06255340 COMPLETED PHASE1
Safety, Tolerability and Pharmacokinetics of Single Rising Doses of BIIB 722 CL and HPβCD in Young Healthy Male Volunteers
NCT02224079 COMPLETED PHASE1
Safety and Pharmacokinetics of Single Rising Oral Doses of BI 224436 ZW in Healthy Male Volunteers.
NCT02183662 COMPLETED PHASE1